 |
|
|
| |
ALL-ORAL 12-WEEK COMBINATION TREATMENT WITH DACLATASVIR AND SOFOSBUVIR IN TREATMENT-EXPERIENCED PATIENTS INFECTED WITH HCV GENOTYPE 3: A SUBANALYSIS OF THE ALLY-3 PHASE 3 STUDY
|
| |
| |
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study - (04/15/15) Hepatology 2015
APASL: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (03/18/15)
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Nelson DR,1 Bernstein D,2 Freilich B,3 Lawitz E,4 Hawkins T,5 Pockros
P,6
Thuluvath P,7 Younes Z,8 Bennett M,9 Ghalib R,10 Ruane P,11 Tong M,12 Bhore R,13 Yin PD,14 Noviello S,13 Rana K14
|
| |
|
|
|
|
|
